BELLUS Health Inc logo

BLU - BELLUS Health Inc News Story

$3.75 -0.1  -2.6%

Last Trade - 5:51pm

Sector
Healthcare
Size
Small Cap
Market Cap £217.8m
Enterprise Value £147.5m
Revenue £10.8k
Position in Universe 4158th / 6849

BRIEF-BELLUS Health Announces First Patient Dosed in its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough

Tue 8th December, 2020 12:15pm
Dec 8 (Reuters) - BELLUS Health Inc  BLU.TO :
    * BELLUS HEALTH ANNOUNCES FIRST PATIENT DOSED IN ITS PHASE
2B
SOOTHE TRIAL OF BLU-5937 FOR THE TREATMENT OF REFRACTORY CHRONIC
COUGH

Source text for Eikon:  ID:nBw7g8mV2a 
Further company coverage:  BLU.TO 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.